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Abstract
Background:  Discrepancies between the conclusions of different meta-analyses (quantitative syntheses of
systematic reviews) are often ascribed to methodological differences. The objective of this study was to
determine the discordance in interpretations when meta-analysts are presented with identical data.
Methods: We searched the literature for all randomized clinical trials (RCT) and review articles on the efficacy
of intravenous magnesium in the early post-myocardial infarction period. We organized the articles
chronologically and grouped them in packages. The first package included the first RCT, and a summary of the
review articles published prior to first RCT. The second package contained the second and third RCT, a meta-
analysis based on the data, and a summary of all review articles published prior to the third RCT. Similar packages
were created for the 5th RCT, 10th RCT, 20th RCT and 23rd RCT (all articles). We presented the packages one at
a time to eight different reviewers and asked them to answer three clinical questions after each package based
solely on the information provided. The clinical questions included whether 1) they believed magnesium is now
proven beneficial, 2) they believed magnesium will eventually be proven to be beneficial, and 3) they would
recommend its use at this time.
Results: There was considerable disagreement among the reviewers for each package, and for each question.
The discrepancies increased when the heterogeneity of the data increased. In addition, some reviewers became
more sceptical of the effectiveness of magnesium over time, and some reviewers became less sceptical.
Conclusion: The interpretation of the results of systematic reviews with meta-analyses includes a subjective
component that can lead to discordant conclusions that are independent of the methodology used to obtain or
analyse the data.
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Background
Health care professionals are strongly encouraged to prac-
tice evidence-based medicine (EBM) when prescribing
treatment for patients [1]. Practicing EBM requires that
health care evidence be succinctly summarised for practi-
tioners. A recommended method is the meta-analysis, i.e.
the quantitative synthesis and estimation of a summary
statistic for the measure of effect [2] based on a systematic
review of the literature (also known as a quantitative sys-
tematic review). A systematic review with a meta-analysis
is often considered the most objective of all types of
reviews for the following reasons: a) the search for articles
is systematic and extensive, b) inclusion and exclusion cri-
teria are explicitly stated, c) a second reviewer often vali-
dates data abstraction, d) data are summarised according
to defined methods, and e) an overall summary statistic
for the estimate of effect is generated according to
accepted statistical methods [3].
Are the processes and interpretation of a systematic review
with a meta-analysis objective? Objectivity implies that a
person's own beliefs, preferences or attributes should not
affect the interpretation of the data. However, meta-anal-
yses performed on the same question by different authors
may lead to different conclusions [4]. The discrepancies
between meta-analyses are often attributed to the subjec-
tive decisions made regarding the procedural issues such
as search strategies, inclusion/exclusion criteria, and
validity of data abstraction. Because these decisions are
subjective and dependent on context, proposed methods
of a meta-analysis should be considered standardizations
(that increase the transparency and reproducibility of the
process) rather than providing an increased level of objec-
tivity. Given the increasing publication of papers describ-
ing how to conduct an appropriate meta-analysis [5-8],
one might expect that the number of discrepancies
between reviews is less now than before. Although this
remains to be determined, it is clear that discrepancies
persist [9].
Although recommendations on how one should explore
the procedural discrepancies between meta-analyses exist
[4], little attention has been given to the actual interpreta-
tion of the numerical results themselves. Discordant inter-
pretations of the numerical results can be due to
variations in knowledge base between readers/authors,
but disagreement is also common among professional
experts with extensive knowledge [10-14]. Another possi-
bility is that the discrepancies reflect a difference in per-
sonal values, resistance to change, and other personal
preferences. For example, different clinicians (and differ-
ent patients) sometimes choose different treatments even
when provided with the same options and the same infor-
mation. Therefore, the objective of this study was to exam-
ine the discordance in interpretations amongst eight
experienced reviewers when presented with exactly the
same data.
Methods
We presented the same data to eight researchers who had
all published systematic reviews and/sor meta-analyses.
In brief, these subjects have different professional back-
grounds (cardiologist, sport medicine physician, internist,
epidemiologist, public health), affiliations (3 different
McGill University hospitals; 2 institutions), and years of
experience (recent PhD obtained with meta-analysis expe-
rience through the Cochrane Collaboration, epidemiolo-
gists with 10–25 years experience).
Each reviewer was shown data from randomised trials
examining whether intravenous magnesium in the post-
myocardial infarction (acute MI) period prevented mor-
tality and arrhythmias. This question was chosen because
there was a known discrepancy between the conclusions
of meta-analyses and a mega-trial on the topic[15] and
one of our interests was whether this feature would differ-
entially affect how reviewers interpreted the meta-analy-
sis. In order to ensure that all reviewers based their
decisions on the same information, they were instructed
to ignore any knowledge they might have through their
personal experience or other readings and to base their
responses only on the information provided to them
through the review articles, original research articles and
meta-analyses. We conducted a systematic review using
exhaustive search strategies [magnesium AND (death or
mortality or survival) AND (coronary or heart or myocar-
dial or myocardium or cardiac or infarct) AND (rand-
omized or randomised or controlled or trial or double
blind or single blind or random or placebo or crossover or
RCT)] and searched Medline, Embase, Cochrane Control-
led Trials Register, Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Science Citation
Index, Cochrane Reviews and Database of Abstracts of
Reviews of Effects (DARE). We then hand-searched rele-
vant titles from the bibliographies and conducted a cita-
tion search on each of the first five published RCTs.
Review articles were retrieved with a shortened search
strategy omitting the last terms referring to RCTs.
Data were abstracted from the articles by a trained
research assistant using standardized data abstraction
forms, and verified by a second trained person. Differ-
ences were resolved by consensus. We assessed the quality
of original manuscripts using the Jadad scale [16,17] and
included the information in the reports to the reviewers
(there was no a priori exclusion criteria or subgroup anal-
ysis). We had initially also used the Chalmers scale
[17,18] but abandoned it when the reliability between
data abstractors was very poor. After data abstraction, we
conducted separate meta-analyses (comparison treatmentBMC Medical Informatics and Decision Making 2008, 8:19 http://www.biomedcentral.com/1472-6947/8/19
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was always placebo) based on the first RCT, the first 3
RCTs, 5 RCTs, 10 RCTs, 20 RCTs and 23 RCTs. At each
time point, the reviewer was given a meta-analysis for
mortality, and a separate meta-analysis for arrhythmias.
Each meta-analysis included random and fixed effects
analyses, a forest plot [8], cumulative forest plot [8], Gal-
braith plot [19], L'Abbe plot [20] and publication bias sta-
tistics and/or plots [8].
The meta-analyses and associated documents were dis-
tributed according to a strict protocol. Each reviewer was
first given the meta-analysis based on the first RCT and
asked a series of questions (see below). Because a meta-
analysis should only be interpreted in the context of the
strengths and weaknesses of the individual studies and the
clinical knowledge at the time, the first meta-analysis was
packaged with 1) the completed standardized data
abstraction for the first RCT (which included any side
effects, co-inverventions, study population, etc described
in the original study), 2) summaries of all clinical review
articles (to provide for knowledge abut standard of care at
the time) and basic science review articles (to provide for
knowledge about hypothesized mechanisms and patho-
physiology at the time) published before the first RCT (n
= 24), and 3) the original publication describing the
methods and results of the first RCT addressing the
research question. Similarly, the second meta-analysis
based on the first 3 RCTs was packaged with the standard-
ized data abstractions and original articles for the 2nd and
3rd RCT, and summaries of all review articles published
prior to the 3rd RCT (n = 6). Similar packages were created
based on the first 5 RCTs, 10 RCTs, 20 RCTs and all 23
RCTs published at the time data abstraction occurred.
After reading the contents of each package (we did not
record the time required but it is estimated between 1–8
hours/package depending on the reviewer and package),
each reviewer responded to three clinical questions
(Appendix I). First, did the reviewer now consider magne-
sium a proven effective treatment for an acute MI (answer
choices strongly disagree to strongly agree)? Second, did
the reviewer believe that magnesium would eventually be
proven an effective treatment for an acute MI (answer
choices strongly disagree to strongly agree)? Third, would
the reviewer recommend magnesium in the treatment of
acute MI (answer choices yes or no only)? These questions
were chosen because they represent the questions clini-
cians face on a daily basis, and the types of questions that
meta-analyses are supposed to help provide answers to.
We restricted answers to Yes/No for the third question
regarding recommendation because a clinician must
make the decision to either recommend or not recom-
mend treatment (e.g. unsure would mean that treatment
is not recommended). This question was especially
important because clinical decisions are based on the
evaluation of potential benefits and potential harms.
Therefore, it is possible to believe a treatment is proven
effective for a particular outcome and still not recommend
treatment if the side effect profile is not adequately
known. It is also possible to recommend a treatment if
there is a high probability that the treatment is beneficial
even if it has not yet been proven. Reviewers were also
encouraged to note specific indications for each question
(e.g. conditions where magnesium is beneficial, harmful
or unsure), and were also encouraged to write notes to
explain their reasoning. We present a qualitative analysis
of the data.
Results
We found 23 RCTs that examined the effect of intravenous
magnesium on mortality in the early post-myocardial inf-
arction period. The meta-analyses showing the individual
studies for each package are shown in Figure 1. The results
of the individual meta-analyses are summarised in Table
1, along with the answers from our reviewers. The fixed
and random effects odds ratios (OR) were similar for the
meta-analyses based on 3 RCTs, 5 RCTs and 10 RCTs, and
each result was statistically significant. The meta-analysis
based on the first 20 RCTs (5th package) included the large
ISIS-4 trial of approximately 50,000 subjects that showed
no effect [21]. At this point, the OR based on fixed effects
models suggested no effect whereas the OR based on the
random effects model suggested a statistically significant
benefit (which is expected to occur whenever a very large
trial shows no effect and smaller trials show an effect).
Similar results were obtained for the last package (23
RCTs).
There was considerable heterogeneity in the reviewers'
interpretations for each meta-analysis for all three ques-
tions. Even after 10 RCTs with a total of 3685 patients,
with similar effect sizes for both random-effects and fixed
effects (OR approximately 0.65 (random effects 95%CI:
0.53, 0.81)) and only mild heterogeneity (I2 = 21%), 1
reviewer strongly agreed the treatment was effective, 4
reviewers agreed it was effective, 2 reviewers were unsure
and 1 reviewer disagreed the treatment was effective. The
discrepancies increased after 20 RCTs, when heterogeneity
increased and the OR from the fixed effects and random
effects models diverged; 1 reviewer strongly agreed the
effect was beneficial, 4 reviewers agreed it was beneficial,
and 3 reviewers disagreed it was beneficial. Similar dis-
crepancies were observed when the reviewers were asked
if they believed the treatment would eventually be proven
beneficial. Finally, when asked if they would recommend
the treatment, 4 reviewers fairly consistently said yes
(excluding the meta-analysis based on 1 RCT), and 4
reviewers fairly consistently said no.BMC Medical Informatics and Decision Making 2008, 8:19 http://www.biomedcentral.com/1472-6947/8/19
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In addition to the discrepancies related to any one indi-
vidual meta-analysis, we examined the patterns of
responses across meta-analyses per reviewer. From the
meta-analysis based on 1 RCT to the meta-analysis based
on 10 RCTs, most reviewers' answers to the question
whether magnesium has been shown to be beneficial
moved from a more negative belief to a more positive
belief, with one exception. Between the meta-analysis
based on 10 RCTs and the meta-analysis based on 23
RCTs, 3 reviewers became more negative about the treat-
ment, 4 did not change their minds and 1 reviewer
became more positive about the treatment.
Although there is not enough power for a statistical anal-
ysis, a qualitative examination of the professional back-
ground of the reviewers does not suggest any strong
tendencies. In general, the cardiologists were negative
towards the use of magnesium, as was the non-practicing
physician (non-cardiologist). Among the four non-cardi-
ologist physicians, all were generally positive, but one
would still not recommend its use.
We also reviewed all the comments made by reviewers but
the data did not lend itself to a formal qualitative review.
We therefore focused on the comments at 10RCTs (bene-
ficial effect with tight confidence intervals) and 20RCTs
(after the large ISIS-4 trial suggested no effect). Of the
three reviewers who were the least in favour of magne-
sium, one remarked that he was almost ready to start rec-
ommending magnesium after 10 RCTs but most of the 
Table 1: Decisions of the 8 reviewers based on the 6 systematic reviews with meta-analyses presented to them.
# RCTS 1 1–3 1–5 1–10 1–20 1–23
N 111 415 597 3685 63047 69505
Fixed OR N/a 0.40 (0.19–0.83) 0.40 (0.28–0.61) 0.64 (0.52–0.79) 1.02 (0.96–1.08) 1.01 (0.96–1.07)
Rand OR N/a 0.40 (0.18–0.86) 0.38 (0.21–0.66) 0.66 (0.53–0.81) 0.65 (0.48–0.87) 0.75 (0.61–0.92)
I2 N/a 0% 0% 21% 59% 59%
I believe magnesium has now been shown to be beneficial for patients during the post-MI period
(C) Disagree Unsure Unsure Disagree Disagree Disagree
(C) Strongly Disagree Unsure Unsure Unsure Disagree Strongly Disagree
(P) Strongly Disagree Agree Agree Agree Agree Agree
(P) Agree Agree Strongly Agree Strongly Agree Strongly Agree Agree
(P) Strongly Disagree Strongly Disagree Disagree Unsure Agree Agree
(P) Unsure Agree Agree Agree Agree Agree
(NP) Strongly Disagree Disagree Disagree Agree Disagree Strongly Disagree
(N) Unsure Agree Agree Agree Agree Agree
I believe magnesium will eventually be shown to be beneficial for patients during the post-MI period
(C) Agree Agree Agree Agree Unsure Disagree
(C) Unsure Unsure Unsure Unsure Strongly Disagree Strongly Disagree
(P) Unsure Agree Agree Strongly Agree Agree Agree
(P) Agree Strongly Agree Strongly Agree Strongly Agree Strongly Agree Agree
(P) Strongly Disagree Strongly Disagree Disagree Unsure Agree Agree
(P) Agree Agree Agree Agree Agree Agree
(NP) Unsure Unsure Unsure Agree Unsure Disagree
(N) Agree Agree Agree Agree Agree Agree
I recommend that magnesium therapy be used in patients during the post-MI period
(C) No No No No No No
(C) No No No No No No
(P) No Yes Yes Yes Yes Yes
(P) No Yes Yes Yes Yes Yes
(P) No No No No No No
(P) No Yes Yes Yes Yes Yes
(NP) No No No Yes No No
(N) No Yes Yes Yes Yes Yes
C: cardiologist, P: other physician, NP: non-practicing physician, N: non-physician
Each column contains the answers from different meta-analyses based on the number of randomized trials provided (top row). The total number of 
subjects in each of the meta-analyses is shown in the second row; the overall fixed effects odds ratio (OR) and random effects OR shown to the 
reviewers are given in rows 3 and 4 (the first trial only examined infarct size and there is no OR for mortality); and the I2 value for heterogeneity is 
shown in row 5. There were three errors that were discovered after some reviewers had answered questions. The differences in the overall effect 
estimates were relatively minor and would not be expected to alter the responses by our reviewers. To remain transparent, we provide the 
numbers provided to the reviewers in this table, and the corrected numbers in Figure 1. The results for each question asked are shown in the 
subsequent rows. The choices for the first two questions were strongly disagree to strongly agree, and the choices for the third question were yes 
or no. In addition to the range of interpretations for any one meta-analysis, reviewer 3 moved from unsure to strongly disagree over the 6 meta-
analyses for the second question whereas reviewer 7 moved in the opposite direction from strongly disagree to agree.BMC Medical Informatics and Decision Making 2008, 8:19 http://www.biomedcentral.com/1472-6947/8/19
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Forest plots that illustrate the data are shown for each of the meta-analysis packages, along with the fixed and random effects  odds ratios at each stage Figure 1
Forest plots that illustrate the data are shown for each of the meta-analysis packages, along with the fixed and random effects odds ratios at each stage. 
The numbers in the graph are slightly different than those found in Table 1 because some data entry errors were discovered at some time points and corrected only after some 
members reviewed the package. The difference in the numbers between Table 1 and Figure 1 are minor and would not be expected to alter the responses by our reviewers. To 
remain consistent and avoid confusion, we have provided only the corrected data in Figure 1, and the numbers provided to the reviewers in Table 1. The first error was in Ras-
mussen 1986 article where the proportions were entered as the raw numbers instead of the frequencies. This was corrected by the next package. A 1988 paper by Rasmussen 
that was a follow-up analysis based on some criticisms in letters to the editors was included in packages RCT 5 and RCT 10 but then omitted later on. Finally, the numbers for the 
Thorgersen 1993 paper were correct in the RCT 10 package but were incorrect in the RCT 20 package due to a transcription error when we switched software; this was cor-
rected for the RCT23 package.
  BMC Medical Informatics and Decision Making 2008, 8:19 http://www.biomedcentral.com/1472-6947/8/19
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trials were small and therefore he preferred to have one
more large study. The other felt that the effect at 10 RCTs
was unreasonably large, and probably reflected publica-
tion bias. The results of the ISIS-4 trial then reversed any
consideration of a real effect for these reviewers. Of those
who generally recommended magnesium use, small sam-
ple sizes up to the 10RCTs were also a concern and a cou-
ple of reviewers limited the recommendation to those
individuals not receiving thrombolysis based on the
mechanism of action discussed in the review articles.
These opinions did not change at 20 RCTs. There were no
comments that suggested reviewers incorporated knowl-
edge which came from sources outside the information
provided to them.
Discussion
Although systematic reviews with meta-analyses are con-
sidered more objective than other types of reviews, our
results suggest that the interpretation of the data remains
a highly subjective process even among reviewers with
extensive experience conducting meta-analyses. The
implications are important. The evidence-based move-
ment has proposed that a systematic review with a meta-
analysis of RCTs on a topic provides the strongest evi-
dence of support and that widespread adoption of its
results should lead to improved patient care. However,
our results suggest that the interpretation of a meta-analy-
sis (and therefore recommendations) are subjective and
therefore depend on who conducts or interprets the meta-
analysis.
Previous authors examining discrepancies among meta-
analyses focused on the subjective decisions regarding
procedural issues leading to different data rather than on
the interpretation of the data [4]. We presented reviewers
with the same meta-analyses and therefore the differences
were due to the actual interpretation of the data. The
GRADE group also found a lack of consensus among
reviewers presented the same data. However, they con-
cluded that this was because some reviewers thought there
was sparse data and some did not [22]. Our reviewers dis-
agreed even when there were 10 RCTs with a total of 3685
patients and homogeneity between studies. Further, we
minimized the effect of content knowledge by providing
a summary of the clinical review articles to all reviewers,
and instructing all reviewers to base their decisions only
on the information provided in the packages; there was no
indication in their written comments suggesting that these
instructions were not followed. Even if the reviewers did
not follow these instructions, the results would still imply
that conclusions are highly dependent on the professional
training of the authors (e.g. differences in understanding
of physiology, epidemiology). For example, the two cardi-
ologists in our group were generally more sceptical of the
effects of treatment. Our study design did not allow for a
detailed analysis of the underlying reasons for these
results and we plan to explore these more fully in a mixed-
methods design in the future. Finally, even though we
provided everyone with the quality score of reporting for
each study based on the Jadad scale [16], it is possible that
the reviewers differentially judged the quality of the stud-
ies.
Evidence-based medicine requires that the clinician make
decisions based on the numerical results observed. Deci-
sion-making and clinical reasoning are complex proc-
esses, and different clinicians (and different patients)
often choose different treatments even when provided
with the same options and the same information. Our
results may simply reflect the same process in the context
of meta-analysis. There is a large body of literature exam-
ining these processes in other areas, and similar processes
may be occurring in the meta-analysis context. Some
selected examples of different frameworks are illustrated
below.
In Gestalt intuition, a subject's decisions are influenced by
the identification of hidden relationships within the
whole context [23]. With reflective practice, experts adapt
their governing analytical premises to the complex prob-
lem at hand [11-13,24]. In decision theory, the expert
attempts to calculate the probabilities of various out-
comes within a specific calculative framework [25,26].
With tacit knowledge, the expert uses implicit decisional
processes of which he/she is not consciously aware [27].
The Bayesian approach recognizes that decision-making is
a two-step process. The decision-maker first decides what
he/she considers is an appropriate estimate for the effect
of the treatment, which is dependent on prior beliefs and
the likelihood function (fixed or random effects model).
In the second step, the decision maker must recognize that
there is a risk associated with whatever decision is taken.
Therefore, the decision maker weighs 1) the risks of doing
harm if they choose to give a treatment they believe is ben-
eficial and the treatment is actually harmful, against 2) the
risks of not providing benefit if they choose not give a
treatment that they believe is ineffective/harmful and the
treatment is actually effective (this is called the loss func-
tion in Bayesian analysis).
Our results suggest that a systematic review with a meta-
analysis must be viewed with the perspective that it repre-
sents one study conducted by specific investigators with a
specific methodology. At each step of the methodology
(defining the general criteria, search strategy, inclusion/
exclusion criteria, data abstraction, and analysis), subjec-
tive decisions are required that could affect the validity of
the study; the relative importance of each will likely
depend on the topic of inquiry and the data acquired. Our
study demonstrates that disagreements in the conclusionsBMC Medical Informatics and Decision Making 2008, 8:19 http://www.biomedcentral.com/1472-6947/8/19
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of systematic reviews with meta-analyses can also be due
to subjective interpretations of the results and not only of
the methodology. Understood in this context, meta-anal-
yses represent one more source of additional information
that allows the scientific community to better understand
a clinical question. It must therefore be read with as much
caution as any other scientific paper.
Our study has potential limitations. Each of our reviewers
had extensive experience conducting systematic reviews
with meta-analyses. We believe that reviewers with less
experience may interpret data very differently and we will
study such reviewers in the future. Other investigators
might have abstracted the data differently than us, or used
different types of analyses (e.g. risk differences instead of
odds ratios). However, this would not affect our results as
all reviewers still viewed the exact same data and the
actual "true" effect of magnesium on the outcome is not
important for the purpose of this study. That said, a sec-
ond trained individual validated all abstracted data and
differences were resolved by consensus. Different review-
ers may prefer different models and rely on different types
of analyses and plots. Therefore, we provided each
reviewer with results based on both fixed and random
effects models, publication bias statistics/plots, forest
plots, Galbraith plots, L'Abbe plots, and the original arti-
cle. If a reviewer requested a specific plot or subgroup
analysis, this was provided. Our data represents heteroge-
neous interpretations from one topic only and we cannot
generalize to other topics or estimate the frequency with
which this might occur. However, we believe this topic
was particularly suited to our objective because it allowed
us to compare decisions between and within reviewers for
meta-analyses with little heterogeneity, and large
amounts of heterogeneity. As we previously stated,
reviewers were asked to base their decisions only on the
information provided in the packages and we cannot be
sure if this occurred. Although we asked reviewers to make
comments on each package, a formal qualitative analysis
was not possible with the data obtained.
Finally, although our data suggest that different reviewers
interpret data differently, this study cannot provide
insight into the reasons why. The answers to this very
important question likely include subtleties and nuances
that are difficult to capture using quantitative methods,
and we will examine these subjective elements in a future
study using a mixed-methods approach.
Conclusion
The interpretation of systematic reviews with meta-analy-
ses is at least partially subjective. Evidence-based practi-
tioners need to be aware that any conclusions and
recommendations based on a systematic review with a
meta-analysis should be read with caution even if the
methodology is rigorous.
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